These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20702265)

  • 1. Validation of cell substrates used for human biologicals: An overview of international regulatory documents.
    Zaninelli P; Barone D
    Toxicol In Vitro; 1990; 4(4-5):720-1. PubMed ID: 20702265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cells, science and health.
    Petricciani JC
    Dev Biol Stand; 1989; 70():3-10. PubMed ID: 2668074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
    Knezevic I; Stacey G; Petricciani J; Sheets R;
    Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous cell substrate considerations.
    Lubiniecki AS
    Bioprocess Technol; 1990; 10():495-513. PubMed ID: 1370028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory aspects of clinical xenotransplantation.
    Schuurman HJ
    Int J Surg; 2015 Nov; 23(Pt B):312-321. PubMed ID: 26408947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA's regulatory role in the ICCVAM process.
    Schechtman LM; Stokes WS
    Altern Lab Anim; 2004 Jun; 32 Suppl 1B():663-8. PubMed ID: 23581155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing Product Quality: a Summary of the Inaugural FDA/PQRI Conference.
    Yu LX; Baker J; Berlam SC; Boam A; Brandreth EJ; Buhse L; Cosgrove T; Doleski D; Ensor L; Famulare J; Ganapathy M; Grampp G; Hussong D; Iser R; Johnston G; Kesisoglou F; Khan M; Kozlowski S; Lacana E; Lee SL; Miller S; Miksinski SP; Moore CM; Mullin T; Raju GK; Raw A; Rosencrance S; Rosolowsky M; Stinavage P; Thomas H; Wesdyk R; Windisch J; Vaithiyalingam S
    AAPS J; 2015 Jul; 17(4):1011-8. PubMed ID: 25840884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of various international guidelines for analytical method validation.
    Chandran S; Singh RS
    Pharmazie; 2007 Jan; 62(1):4-14. PubMed ID: 17294806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preparation and validation of stock cultures of mammalian cells.
    Facklam TJ; Geyer S
    Bioprocess Technol; 1991; 13():54-85. PubMed ID: 1367151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines.
    Hess RD; Weber F; Watson K; Schmitt S
    Vaccine; 2012 Apr; 30(17):2715-27. PubMed ID: 22342707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework.
    Karalis VD
    Drug Res (Stuttg); 2016 Jan; 66(1):1-6. PubMed ID: 25894088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for use in the International Conference on Harmonisation Regions; Annex 4C on Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15992-3. PubMed ID: 19507323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous cell lines as substrates for biologicals. Draft position paper. Pharmaceutical Manufacturer's Association.
    Dev Biol Stand; 1989; 70():285-7. PubMed ID: 2759355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.